It is now generally agreed that multiple opioid receptors exist in the mammalian central nervous system, but the roles they play in various opioid-mediated effects, and particularly in analgesia, are still unclear. Recent studies indicate that three major levels or areas of the CNS are critical in the control of pain: the dorsal horn of the spinal cord, the rostroventral medulla (RVM), and the periaqueductal gray (PAG). Thus identifying the opioid receptor types present in these areas is critical to our understanding of analgesia. As an approach to determining opioid receptor multiplicity, we recently analyzed the displacement of three ligands somewhat selective for different receptors: dihydromorphine (DHM) (mu); D-ala2-D-leu5- enkephalin (DADLE) (delta); and ethylketocyclazocine (EKG) (kappa). Using a computer model system, we found the best fit was with 4 distinct sites, two specific for DHM, one for DADLE, and one for EKG. We proposed to continue this work by testing the ability of B-endorphin and dynorphin, and their fragments, to displace these three tritiated ligands, as well as ligands that are highly selective for particular sites. The latter will include 3H- Tyr-D Ala-Gly-NMe-Phe-Gly-ol (3H-DAGO), which is mu specific; 3H-D-Pen2,5-Enkephalin (3H-DPEN), delta-specific; and 3H-U-50,488H, kappa-specific. We will apply this technique to each of three major CNS regions that have been implicated in opioid analgesia, with studies being conducted in both naive and morphine-tolerant animals. We will also determine displacement after treatment of tissue with alkylating agents, such as B-CNA or B-FNA, which inactivate binding sites in a selective manner. Since B-endorphin and dynorphin may also interact with sites not labelled by any of these ligands, we will also determine binding directly, using the tritiated peptides. Finally, we will use cross- linking reagents to label covalently the B-endorphin receptors. They can then be identified by polyacrylamide gel electrophoresis in SDS, and after further purification, tested for cross-reactivity to antibodies to the mu opiate receptor.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA002643-08
Application #
3207477
Study Section
(SRCD)
Project Start
1981-01-01
Project End
1992-06-30
Budget Start
1988-07-01
Budget End
1989-06-30
Support Year
8
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Riba, Pal; Ben, Yong; Nguyen, Thi M-D et al. (2002) [Dmt(1)]DALDA is highly selective and potent at mu opioid receptors, but is not cross-tolerant with systemic morphine. Curr Med Chem 9:31-9
Riba, Pal; Ben, Yong; Smith, Andrew P et al. (2002) Morphine tolerance in spinal cord is due to interaction between mu- and delta-receptors. J Pharmacol Exp Ther 300:265-72
Gant, T M; Riba, P; Lee, N M (2001) Morphine tolerance in mice is independent of polymorphisms in opioid receptor sequences. Brain Res Bull 55:59-63
He, L; Lee, N M (1998) Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord. J Pharmacol Exp Ther 285:1181-6
He, L; Lee, N M (1997) DynorphinA-(2-17) restores spinal/supraspinal morphine synergy in morphine-tolerant mice. J Pharmacol Exp Ther 280:1210-4
Lee, N M (1995) Dynorphin A: a rectifying peptide. NIDA Res Monogr 147:161-9
Lane, C M; Jones, C R; Reisine, T et al. (1995) Alteration of OBCAM conformation as a result of opioid receptor expression and opioid ligand treatment. Brain Res 698:15-22
Kalyuzhny, A; Lee, N M; Elde, R (1995) An opioid binding protein is specifically down-regulated by chronic morphine treatment in dorsal root and trigeminal ganglia. Neuroscience 66:943-9
Pentel, P R; Wananukul, W; Hooke, L P et al. (1995) Effects of high intravenous doses of dynorphin A(1-13) on tail flick latency and central nervous system histology in rats. Pharmacol Biochem Behav 51:387-90
Hooke, L P; He, L; Lee, N M (1995) Dynorphin A modulates acute and chronic opioid effects. J Pharmacol Exp Ther 273:292-7

Showing the most recent 10 out of 26 publications